Statins, ventricular arrhythmias and heart rate variability in patients with implantable cardioverter defibrillators and coronary heart disease

Cardiology

Volumn 104, Issue 4, 2005, Pages 210-214

  Riahi, Sam ^a,b   Schmidt, Erik Berg ^a   Christensen, Jeppe Hagstrup ^a   Heath, Finn ^a   Pedersen, Anders Kirstein ^c   Nielsen, Jens Cosedis ^c   Mølgaard, Henning ^c   Toft, Egon ^a,b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Coronary heart disease; Heart rate variability; HMG CoA reductase inhibitors; Implanted cardioverter defibrillator; Plasma lipids

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEFIBRILLATOR; DRUG EFFECT; FEMALE; HEART RATE VARIABILITY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTI-ARRHYTHMIA AGENTS; BIOLOGICAL MARKERS; CHOLESTEROL; COMBINED MODALITY THERAPY; CORONARY DISEASE; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LIPIDS; MALE; MIDDLE AGED; STATISTICS; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; TRIGLYCERIDES; VENTRICULAR FIBRILLATION;

EID: 26044452968     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088175     Document Type: Article

References (18)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
2. Lewis SJ, Sacks FM, Mitchell JS, et al: Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998;32:140-146.
3. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-1445.
4. Downs JR, Clearfield M, Weis S, et al: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622.
5. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
6. Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-2016.
7. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-1650.
8. Liao JK: Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 2002;86:5-18.
9. Riahi S, Christensen JH, Toft E, Skou HA, Schmidt EB: HMG-CoA reductase inhibitors improve heart rate variability in patients with a previous myocardial infarction. Pharmacol Res 2002;45:479-483.
10. De Sutter J, Tavernier R, De Buyzere M, Jordaens L, De Backer G: Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 2000;36:766-772.
11. Dotani MI, Elnicki DM, Jain AC, Gibson CM: Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 2000;86:1128-1130.
12. Gregoratos G, Abrams J, Epstein AE, et al: ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 2002;106:2145-2161.
13. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
14. Task Force of the European Society of Cardiology and North American Society of Pacing and Electrophysiology: Heart rate variability: standards of measurement, physiological interpretation and clinical use.. Circulation 1996;93:1043-1065.
15. Stein PK, Kleiger RE: Insights from the study of heart rate variability. Annu Rev Med 1999;50:249-261.
16. Christensen JH, Toft E, Christensen MS, Schmidt EB: Heart rate variability and plasma lipids in men with and without ischaemic heart disease. Atherosclerosis 1999;145:181-186.
17. Pehlivanidis AN, Athyros VG, Demitriadis DS, Papageorgiou AA, Bouloukos VJ, Kontopoulos AG: Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2001;157:463-469.
18. Cannon CP, Braunwald E, MacCabe BS, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:495-504.